Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 204.17M | 201.49M | 196.83M | 196.04M | 197.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 204.17M | 201.49M | 196.83M | 196.04M | 197.05M |
| Cost of Revenue | 98.61M | 97.03M | 91.60M | 89.35M | 88.80M |
| Gross Profit | 105.56M | 104.46M | 105.23M | 106.68M | 108.25M |
| SG&A Expenses | 113.08M | 108.38M | 99.80M | 95.39M | 93.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 248.04M | 241.88M | 228.63M | 222.90M | 221.81M |
| Operating Income | -43.87M | -40.39M | -31.81M | -26.86M | -24.76M |
| Income Before Tax | -35.95M | -29.84M | -15.49M | -7.56M | -7.97M |
| Income Tax Expenses | 38.06M | 36.70M | -2.67M | -1.16M | 3.28M |
| Earnings from Continuing Operations | -74.00 | -66.54 | -12.82 | -6.40 | -11.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.00M | -66.54M | -12.82M | -6.40M | -11.25M |
| EBIT | -43.87M | -40.39M | -31.81M | -26.86M | -24.76M |
| EBITDA | -36.30M | -32.81M | -24.27M | -19.39M | -17.38M |
| EPS Basic | -0.58 | -0.52 | -0.10 | -0.05 | -0.09 |
| Normalized Basic EPS | -0.18 | -0.15 | -0.08 | -0.04 | -0.04 |
| EPS Diluted | -0.58 | -0.52 | -0.11 | -0.06 | -0.09 |
| Normalized Diluted EPS | -0.18 | -0.15 | -0.08 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 511.35M | 510.99M | 511.90M | 515.36M | 519.87M |
| Average Diluted Shares Outstanding | 511.35M | 510.99M | 511.90M | 517.14M | 521.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |